Join the club for FREE to access the whole archive and other member benefits.

Crispr injection could reduce chance of heart attack

Verve Therapeutics treatment targets PCSK9 gene

10-May-2019

Key points from article :

Radical gene therapy that aims to drastically reduce the risk of heart attack.

Would change from a chronic care approach to a ‘one and done’ approach.

Therapy will modify genes in the liver that are involved in making low-density lipoprotein (LDL).

People with only one working copy of PCSK9 gene are remarkably resistant to heart attack.

Patients will be injected with nanolipids which use Crispr-Cas9 to disables PCSK9.

Researchers hope to trial the therapy within the next three years

Verve Therapeutics, which will develop the therapy, has received $58.5m from investors.

Mentioned in this article:

Click on resource name for more details.

Martin Farrall

University Lecturer in Cardiovascular Genetics at Oxford University.

Sekar Kathiresan

Physician scientist, human geneticist and professor at Harvard Medical School.

Topics mentioned on this page:
Gene Therapy, Heart Disease